GlassScriptPhysician profile
Christopher John Joseph
NPI 1902002553
$1,863.43
in general payments reported to CMS, 2019-2025
17 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $257 · 2021: $513 · 2022: $423 · 2023: $139 · 2024: $159 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $850.68 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Abbvie INC. | $257.25 | 2022-2023 | |
| Allergan, INC. | $250.81 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $126.23 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $53.66 | 2024 | Xdemvy |
| New World Medical,INC. | $51.95 | 2021 | |
| Henry Schein Medical Systems, INC. | $50.60 | 2019 | |
| Dompe US, INC. | $38.60 | 2019-2022 | |
| Rxsight INC | $33.67 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $25.86 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.59 | 2022 | |
| Shire North American Group INC | $20.49 | 2019 | |
| Bausch & Lomb Americas INC. | $20.23 | 2023 | Vyzulta, Prolensa, Lotemax Sm |
| Oyster Point Pharma, INC. | $19.97 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $17.14 | 2023 | Dsuvia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $13.67 | 2019 | |
| Thea Pharma INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.